#USA #Cambridge #ALS #NeuroSense #PrimeC

NeuroSense's Innovative Strategy to Fast-Track PrimeC Approval in ALS

NeuroSense Therapeutics Ltd., a late-stage clinical biotechnology company based in Cambridge, Massachusetts, has unveiled a groundbreaking strategy for PrimeC, its lead drug candidate for amyotrophic lateral sclerosis (ALS). This innovative plan aims to streamline the regulatory submission process, significantly reducing the time and costs associated with traditional drug development pathways.

Redefining Drug Development in ALS

The neurology field has often been encumbered by lengthy and expensive trial processes, making timely access to effective therapies challenging for ALS patients. Recognizing this issue, NeuroSense has redesigned its development approach to incorporate three focused studies instead of a single large-scale trial, traditionally seen in the industry. Each study is purpose-built to address critical questions raised by stakeholders, including regulators and healthcare providers.

NeuroSense's new strategy will leverage the promising data gathered from its Phase 2b PARADIGM study, which demonstrated significant effects on functional decline and beneficial changes across several disease biomarkers. The company has now received FDA clearance to initiate its pivotal Phase 3 PARAGON trial, setting the stage for a more targeted and cost-effective development path.

AI-Driven Insights and Comparative Research

Central to NeuroSense's plan is the AI-enabled characterization of PrimeC's unique formulation. PrimeC is a fixed-dose combination of two FDA-approved drugs, designed to work in harmony to address multiple biological pathways involved in ALS progression. A recent clinical pharmacokinetic study showed that, unlike the individual components taken separately, PrimeC produces a synchronized pharmacological effect. By employing AI modeling, NeuroSense aims to quantify this formulation's unique advantages, further establishing the drug's differentiation in clinicians’ and payers' eyes.

Additionally, the company will conduct an active-comparator clinical trial that directly pits PrimeC against edaravone, a well-established ALS therapy. Such direct comparisons are not commonly performed in ALS research, making this study particularly critical in demonstrating PrimeC's clinical value and market potential.

A Streamlined Pathway for Earlier Access

NeuroSense's strategy also includes a re-evaluation of its Phase 3 trial design to create an optimized approach, which should be shorter and involve fewer participants diagnosed with ALS but in an earlier disease stage. This refinement aims to support earlier regulatory submissions, potentially allowing for a quicker path to approval. The company plans to engage the FDA to explore whether current data may support full approval or an Accelerated Approval pathway, which would enable an additional post-approval study if required.

In parallel, NeuroSense is also pursuing a path for expedited access in Canada. After completing the preliminary pre-New Drug Submission process with Health Canada, the company is preparing a full New Drug Submission for PrimeC, aimed for December 2026. Successful acceptance of this submission could make PrimeC available to Canadian patients based on existing data.

A Patient-Centric Approach

Alon Ben-Noon, CEO of NeuroSense, acknowledged the pressing timeframe of ALS patients, stressing that the goal of the strategy is to reduce the duration from data collection to treatment availability. He stated, “This plan is our answer. It is faster, it costs less, and it produces a stronger package.” With this new direction, NeuroSense aims to provide hope and effective treatment options more swiftly to those afflicted by this devastating disease.

About NeuroSense and PrimeC

NeuroSense Therapeutics is dedicated to pioneering novel treatments for severe neurodegenerative diseases, primarily focusing on ALS and Alzheimer's disease. PrimeC's unique formulation involves a fixed-dose combination that targets key biological pathways contributing to neurodegeneration.

Given the soaring ALS diagnosis rates, estimated to rise by 24% by 2040 in the US and EU, the urgency for an innovative solution is palpable, with more than 5,000 patients diagnosed annually in the United States alone. NeuroSense's efforts with PrimeC could make a remarkable difference in the landscape of ALS treatment.

For ongoing insights and updates, individuals interested can follow NeuroSense on various social media platforms and visit their official website for investor information and progress reports related to their significant work against ALS.